title: Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma.
abstract: A novel layered double hydroxide (LDH) nanoparticle/thermogel composite drug delivery system (DDS) for sustained release of brimonidine (Bri) has been designed, prepared, and characterized in this study for treatment of severe glaucoma. Brimonidine is first loaded onto LDH (Bri@LDH) nanoparticles, which are then dispersed in the thermogel consisting of plenty of micelles based on poly(dl-lactic acid-co-coglycolic acid)-polyethylene glycol-poly(dl-lactic acid-co-coglycolic acid) (PLGA-PEG-PLGA) copolymer. The Bri@LDH/Thermogel DDS containing 125.0 μg/g of brimonidine has been found to sustainably release the drug for up to 144 h, significantly extending the drug release period compared to that from Bri@LDH nanoparticles. The Bri@LDH/Thermogel DDS is not cytotoxic to human corneal epithelial cells and shows good biocompatibility. In vivo drug release from the special contact lens made of Bri@LDH/Thermogel DDS has been sustained for at least 7 days, which more effectively modulates the relief of intraocular pressure (IOP). Thus, the Bri@LDH/Thermogel DDS is a promising drug delivery alternative that can be used for treatment of severe glaucoma.
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence for Functional Nanomaterials, The University of Queensland , Brisbane, Queensland 4072, Australia.|State Key Laboratory of Molecular Engineering of Polymers, Fudan University , Shanghai 200433, China.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Sun
authors.forename: Yuan
authors.initials: Y
authors.lastname: Lei
authors.forename: Zhaoxing
authors.initials: Z
authors.lastname: Dai
authors.forename: Xi
authors.initials: X
authors.lastname: Liu
authors.forename: Taomin
authors.initials: T
authors.lastname: Huang
authors.affiliation: State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan University , Shanghai 200032, China.
authors.forename: Jihong
authors.initials: J
authors.lastname: Wu
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence for Functional Nanomaterials, The University of Queensland , Brisbane, Queensland 4072, Australia.
authors.forename: Zhi Ping
authors.identifier: http://orcid.org/0000-0001-6070-5035
authors.initials: ZP
authors.lastname: Xu
authors.affiliation: State Key Laboratory of Medical Neurobiology, Institutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan University , Shanghai 200032, China.
authors.forename: Xinghuai
authors.initials: X
authors.lastname: Sun
mesh_terms: D000068438:Brimonidine Tartrate / Q000737:chemistry*; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D005901:Glaucoma; D006801:Humans; D011092:Polyethylene Glycols
chemical_list: D003692:Delayed-Action Preparations; D011092:Polyethylene Glycols; D000068438:Brimonidine Tartrate
keywords: brimonidine; drug delivery system (DDS); glaucoma; intraocular pressure (IOP); layered double hydroxide (LDH) nanoparticles; thermogel